- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
—
BASINGSTOKE, England and PHILADELPHIA, July 4BASINGSTOKE, England and PHILADELPHIA, July 4 /PRNewswire/ -- Shire Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2008 earnings on Thursday 31 July 2008
Results press release will be issued at: 12:00 BST / 07:00 EDT Investor meeting and conference call time: 14:30 BST / 09:30 EDT
Investor & Analyst meeting and conference call:
Angus Russell, Chief Executive Officer, Graham Hetherington, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie Grégoire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:30 BST/9:30 EDT.
The meeting will take place at Holborn Bars, 138-142 Holborn, London EC1 2NQ.
Please email claire.rowell@fd.com to register to attend this meeting in London.
The details of the conference call are as follows:
UK and International dial in +44-(0)-203-023-4496 US dial in: +1-866-966-5335 Password/Conf ID: Shire
Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:
UK and International dial in +44-(0)-208-196-1998 US dial in +1-866-583-1035 Pin code 3008632 Webcast replay: http://www.shire.com, in the investors section
Notes to editors
SHIRE LIMITED
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact:
Investor Relations Souheil Salah (Rest of the World) +44-1256-894-160 Emily Berish (North America) +1-484-595-8546
Related Pharmalicensing company profiles
Related news
Related News
- Shire plc: Long Term Incentive Plan
- Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
- Publication of Supplementary Prospectus
- Application for Listing of Shire Limited Ordinary Shares
- Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
- Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
- Shire to Introduce a New UK Listed Holding Company
- GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
- Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
- Genmab Announces 2008 First Quarter Results
Latest News
- Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
- New Treatment Launched to Help Improve Symptoms in People Suffering From Overactive Bladder
- Global Medical Devices Company Selects Varicent Performance Management Software
- Get Answers to the Burning Questions About Women's Health
- Essilor : Nomination of Hubert Sagnieres
- Essilor's First-Half 2008 Results
- Reese Witherspoon Visits Brazil to Spread Message of Female Empowerment as Avon's Global Ambassador
- Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
- Genmab Announces 2008 First Half Year Results
- Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us